​

Celldex Therapeutics (CLDX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

CLDX Stock Forecast

Celldex Therapeutics (CLDX) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $63.00, with a high of $80.00 and a low of $46.00. This represents a 244.26% increase from the last price of $18.30.

$15 $28 $41 $54 $67 $80 High: $80 Avg: $63 Low: $46 Last Closed Price: $18.3

CLDX Stock Rating

Celldex Therapeutics stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (90.00%), 1 Hold (10.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 1 9 Strong Sell Sell Hold Buy Strong Buy

CLDX Price Target Upside V Benchmarks

TypeNameUpside
StockCelldex Therapeutics244.26%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts114
Avg Price Target$46.00$46.00$57.00
Last Closing Price$18.30$18.30$18.30
Upside/Downside151.37%151.37%211.48%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 252102--14
Mar, 251102--13
Feb, 25192--12
Jan, 25192--12
Dec, 24192--12
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 20, 2025Morgan Stanley$46.00$19.88131.39%151.37%
Oct 29, 2024Joseph PantginisH.C. Wainwright$80.00$27.12194.99%337.16%
Sep 25, 2024Derek ArchilaWells Fargo$44.00$36.0222.15%140.44%
Jun 17, 2024Alex ThompsonStifel Nicolaus$58.00$34.9166.14%216.94%
Nov 10, 2023Derek ArchilaWells Fargo$27.00$25.784.73%47.54%
Nov 11, 2022Guggenheim$63.00$39.8957.93%244.26%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 20, 2025Morgan StanleyOverweightinitialise
Jan 08, 2025CitigroupBuyBuyhold
Oct 29, 2024H.C. WainwrightBuyBuyhold
Oct 28, 2024Cowen & Co.BuyBuyhold
Oct 28, 2024Wolfe ResearchBuyBuyhold
Oct 28, 2024GuggenheimBuyBuyhold
Oct 07, 2024CitigroupBuyinitialise
Sep 30, 2024Goldman SachsNeutralinitialise
Sep 27, 2024Leerink PartnersMarket Performdowngrade
Sep 26, 2024Wolfe ResearchBuyPeer Performdowngrade

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.02$-1.64$-2.62$-2.92$-2.45----
Avg Forecast$-1.77$-1.64$-2.38$-2.80$-2.45$-3.28$-3.79$-3.75$-1.07
High Forecast$-0.91$-0.84$-1.61$-2.60$-2.35$-2.93$-2.85$-3.15$-0.61
Low Forecast$-3.21$-2.97$-3.71$-2.95$-2.59$-3.55$-4.82$-4.28$-1.74
Surprise %14.12%-10.08%4.29%-----

Revenue Forecast

$0 $100M $200M $300M $400M $500M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$7.42M$4.65M$2.36M$6.88M$7.02M----
Avg Forecast$4.20M$5.34M$988.00K$4.11M$6.83M$4.00M$2.84M$51.13M$328.93M
High Forecast$6.82M$8.67M$1.41M$4.95M$8.32M$5.95M$2.85M$76.03M$489.11M
Low Forecast$2.63M$3.34M$742.71K$3.22M$5.67M$2.68M$2.82M$34.22M$220.10M
Surprise %76.62%-12.90%138.56%67.57%2.80%----

Net Income Forecast

$-250M $-200M $-150M $-100M $-50M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-59.78M$-70.51M$-122.78M$-141.43M$-157.86M----
Avg Forecast$-85.92M$-79.46M$-86.68M$-141.43M$-119.81M$-157.14M$-185.74M$-180.08M$-51.60M
High Forecast$-44.15M$-40.83M$-69.35M$-113.14M$-114.06M$-142.17M$-138.09M$-152.63M$-29.41M
Low Forecast$-155.65M$-143.95M$-104.02M$-169.71M$-125.56M$-172.12M$-233.39M$-207.53M$-84.26M
Surprise %-30.42%-11.26%41.64%-31.76%----

CLDX Forecast FAQ

Is Celldex Therapeutics stock a buy?

Celldex Therapeutics stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Celldex Therapeutics is a favorable investment for most analysts.

What is Celldex Therapeutics's price target?

Celldex Therapeutics's price target, set by 10 Wall Street analysts, averages $63 over the next 12 months. The price target range spans from $46 at the low end to $80 at the high end, suggesting a potential 244.26% change from the previous closing price of $18.3.

How does Celldex Therapeutics stock forecast compare to its benchmarks?

Celldex Therapeutics's stock forecast shows a 244.26% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Celldex Therapeutics over the past three months?

  • April 2025: 14.29% Strong Buy, 71.43% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 7.69% Strong Buy, 76.92% Buy, 15.38% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 8.33% Strong Buy, 75.00% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.

What is Celldex Therapeutics’s EPS forecast?

Celldex Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.28, marking a 33.88% increase from the reported $-2.45 in 2024. Estimates for the following years are $-3.79 in 2026, $-3.75 in 2027, and $-1.07 in 2028.

What is Celldex Therapeutics’s revenue forecast?

Celldex Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $4M, reflecting a -42.96% decrease from the reported $7.02M in 2024. The forecast for 2026 is $2.84M, followed by $51.13M for 2027, and $328.92M for 2028.

What is Celldex Therapeutics’s net income forecast?

Celldex Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-157M, representing a -0.45% decrease from the reported $-158M in 2024. Projections indicate $-186M in 2026, $-180M in 2027, and $-51.598M in 2028.